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Summary
Soft tissue sarcomas account for about 1% of all malig-
nancies. The increase in incidence of soft tissue sarcomas
during the recent decades may predominantly be attrib-
uted to AIDS-related Kaposi’s sarcoma; when this tumor
is excluded, conclusive evidence for an age-adjusted
increase is lacking. Beside the well investigated role of the
human immunodeficiency virus 1 (HIV-1) and the human
herpesvirus 8 (HHV-8) in the tumorigenesis of AIDS-re-
lated Kaposi’s sarcoma and several inherited disorders,
considerable evidence support a relationship between
occupational chemicals as vinyl chloride, phenoxyacetic
acid herbicides, chlorphenols, dioxin, medicinal mea-
sures as Thorotrast exposure and therapeutic irradiation,
and the development of soft tissue sarcoma. Hormones
and chronic repair processes are further probably sar-
coma-promoting factors. Considering the rarity of soft
tissue sarcomas despite the vast portion that soft tissues
comprise in the human body, additional knowledge on
the tumorigenesis of soft tissue sarcomas might con-
siderably contribute to the understanding of the etiologic
pathways of malignant tumors in humans.
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Zusammenfassung
Weichteilsarkome stellen etwa 1% aller bösartigen Neubil-
dungen. Der in den vergangenen Jahrzehnten beobach-
tete Inzidenzanstieg geht fast ausschließlich auf die ra-
sante Zunahme an AIDS-assoziierten Kaposi-Sarkomen
zurück. Bei Außerachtlassung dieses Tumors gibt es bisher
keinen schlüssigen Beweis für eine wirkliche alterskor-
rigierte Häufigkeitszunahme der Weichteilsarkome.Neben
der gut untersuchten Rolle des HIV-1-Virus und des huma-
nen Herpes-Virus 8 bei der Entstehung des AIDS-asso-
ziierten Kaposi-Sarkoms und einigen prädisponierenden
genetischen Erkrankungen existieren starke Hinweise für
einen Zusammenhang zwischen Industriegiften wie Vinyl-
chlorid, Phenoxyessigsäure-Herbiziden, Chlorphenolen,
Dioxinen, medizinischen Maßnahmen wie therapeutischer
Bestrahlung oder dem Einsatz von Thorotrast, und der
Entwicklung von Weichteilsarkomen. Hormone und chro-
nische Reparaturprozesse sind weitere wahrscheinlich
fördernde Einflüsse auf die Entstehung von Weichteil-
sarkomen. Die Tatsache, daß trotz des großen Anteils, den
die Binde- und Stützgewebe an der Körpermasse stellen,
nur selten maligne Tumoren von diesen Strukturen aus-
gehen, läßt hoffen, daß ein besseres Verständnis der an
der Kanzerogenese von Weichteilsarkomen beteiligten
Mechanismen in der Zukunft wichtige Erkenntnisse über
die Entstehung menschlicher Tumoren liefern kann.
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Introduction
Sarcomas comprise a wide spectrum of tumors. With the dif-
ferent biologic behavior of the sarcoma subtypes and the
differences in age, gender, and race distribution [1], it is likely
that different and possibly specific etiologic factors are in-
volved in the tumorigenesis of these neoplasms. Due to the
rarity of soft tissue sarcomas, a considerable part of the
currently available etiologic data is derived from series with a
very small number of events or single case reports.
Incidence
About 1% of malignancies arise from connective or supporting
tissue [1, 2]. Among 1,220,100 new cancer cases estimated for
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the US in the year 2000, 8,100 cases of malignant soft tissue
tumors (0.7%) have been prognosticated [3]. When AIDS-re-
lated Kaposi’s sarcoma is excluded, both European and US
cancer registry data provide no conclusive evidence for an in-
creasing incidence of soft tissue sarcomas [2, 4–6]. Beside 
the well established relationship between human immuno-
deficiency virus 1 (HIV-1), several infectious, environmental,
occupational, and medical agents have been suspected for an
involvement in the tumorigenesis of soft tissue sarcomas.
Inherited Disorders
Several genetically determined syndromes as retinoblastoma,
Werner’s disease, Li-Fraumeni syndrome, von Reckling-
hausen’s disease, Carney’s triad, the lymphedema-distichiasis
syndrome and genetically determined immunodeficiency
diseases are linked with an elevated risk to develop soft tissue
sarcomas [2]. Most families with the Li-Fraumeni syndrome
bear mutations of the tumor suppressor gene p53 [2] which is
involved in the pathogenesis of a great variety of malignancies
and has shown to be linked to sarcoma development in mice
[7]. Alterations in the retinoblastoma gene have been found
associated both in sporadic and in sarcomas arising in retino-
blastoma survivors [2].
Lymphedema
Beside heritable lymphedema, the acquired disease, for
instance after treatment of breast cancer, is associated with an
increased risk of developing lymphangiosarcoma [2].
Viruses
Before the beginning of the AIDS epidemic, Kaposi’s sarcoma
was a rare tumor chiefly effecting elderly men [8]. Today, this
tumor is common in patients infected with the human
immunodeficiency virus 1 (HIV-1) with an up to 70,000-fold
increased risk, compared with age- and population-matched
controls [8]. Recent evidence suggests that HIV-1 might play a
more indirect role in the etiologic process of Kaposi’s sarcoma
by causing immunosuppression and facilitating co-infection
with the human herpesvirus 8 (HHV-8). HHV-8 has been
found associated to almost all forms of Kaposi’s sarcoma and
seems to be a necessary but not sufficient condition for the
development of this tumor [2, 8]. Other data, however, support
a direct involvement of HIV-1 in the tumorigenesis of Kaposi’s
sarcoma [8].
Occupational and Environmental Risk Factors
Various occupational and environmental risk factors have
been linked to an increased risk of soft tissue sarcoma.There is
a well established relationship between herbicides as phenoxy-
acetic acid derivatives and their highly toxic contaminant
2,3,7,8-tetrachlorodibenzo-paradioxin (dioxin) and the devel-
opment of soft tissue sarcomas [1, 2]. Several studies demon-
strated an excess of soft tissue sarcomas in agricultural and
forestry workers exposed to phenoxyacetic herbicides and
chlorphenols [1, 2] with malignant fibrous histiocytoma and
leiomyosarcoma representing the most responsive sarcoma
subtypes [1]. Exposure to wood and saw dust has been found
associated with an increased risk of leiomyosarcoma [1]. The
relationship between the occupational risk factors vinyl chloride
and inorganic arsenic and hepatic angiosarcoma is well docu-
mented [2, 5, 9]. Abattoir and meat packing workers were
found to be at an elevated risk of soft tissue sarcoma [1, 2].
Several hypotheses (packing-associated chemicals, zoonotic
oncogenic viruses) have been discussed to explain this pheno-
menon [2]. Dermatofibrosarcoma protuberans and leiomyo-
sarcoma are sarcoma subtypes found associated with work in a
meat packing plant [1].
Hormones
In one study, 4 cases of angiosarcoma of liver have been at-
tributed to the use of androgenic-anabolic steroids for a time
period between 15 months and 23 years and with a latent
period of 2–35 years from the onset of treatment [9]. One case
of hemangiopericytoma has been observed following long-
term estrogen treatment in a man [10]. Several epidemiologic,
animal experimental, and molecular data suggest an involve-
ment of hormonal stimulation in the tumorigenesis of leiomyo-
sarcoma. In contrast to sarcoma in general, leiomyosarcoma is
more common in women than in men, mainly – but not only –
due to uterine leiomyosarcoma [2]. Hormone receptors have
been found not only in uterine leiomyosarcoma but also in
leiomyosarcomas of blood vessels [11, 12]. Gonadal hormones
like estrogens stimulate the growth of uterine leiomyomas, and
low-grade smooth muscle tumors metastatic to the lung have
been shown to regress after oophorectomy [13]. One study
showed an excess of uterine leiomyosarcoma and stroma sar-
coma in women taking anticontraceptive drugs [14]. In Golden
Syrian hamster, a treatment with androgens combined with
estrogens (testosterone propionate / diethylstilbestrol) induced
leiomyosarcomas of the uterus, the spermatic cord and the epi-
didymis with a success rate of up to 100% [15]. After trans-
plantation, these tumors are initially responsive to hormones
[15]. Hudson et al. [16] demonstrated that the application of
testosterone propionate and diethylstilbestrol decreases the
expression of a glutathione S-transferase enzyme in the vas
deferens of Golden Syrian hamsters. Since the application of
testosterone alone results only in hyperplasia of the vas def-
erens of the hamsters without malignant change, and pro-
liferating cells are known to express lower levels of glutathione
S-transferase, which belongs to a superfamily of detoxification
enzymes, the authors hypothesized that the androgenic prolif-
erative effect on smooth muscle cells might increase their
vulnerability to genotoxic effects [16]. We observed an intra-
testicular tumor which met all immunohistochemical criteria of
leiomyosarcoma in a 32-year-old man 9 years after a 5-year
history of high-dose doping with the synthetic androgen 
4-chloro-1-dehydro-17a-methyltestosterone (Oral-Turinabol®,
VEB Jenapharm, Jena,Thuringia, GDR) as a high-performance
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weight-lifter in the former German Democratic Republic
[17–19]. In this case, a possible promoting role of the doping
medication was supported by the extreme rarity of intratesti-
cular leiomyosarcoma [20] and the uncommon young age of
the patient with leiomyosarcoma preferably affecting the
elderly male [21].
Irradiation
The relationship between irradiation and the development of
soft tissue sarcomas is well established [2]. The incidence of
sarcomas after radiotherapy has been estimated between
0.03% and 0.8% [22, 23]. As among sarcomas found associated
with a history of long-standing inflammation, malignant
fibrous histiocytoma is the most frequent subtype among irra-
diation-induced sarcomas [2, 22–24]. Although sarcomas cer-
tainly represent only a minority of all radiation-induced neo-
plasms [25], it has been estimated that about 5% of sarcomas
may be attributed to previous irradiation [26]. The diagnosis of
an irradiation-induced sarcoma needs histologically proven
development of a sarcoma after an appropriate long latent
period (3–5 years) in an irradiated area which was without evi-
dence of such tumor before the irradiation [23]. Since low-dose
irradiation seems not to increase the risk of soft tissue sarcoma
significantly [22, 27], one can speculate that beside the irradia-
tion-induced DNA damage chronic repair processes might be
involved in the tumorigenesis of irradiation-induced sarcomas.
Various sarcomas, mainly hepatic angiosarcomas, have been
observed after application of Thorotrast, a radioactive contrast
medium used until the 1950s [2].
Chronic Repair Processes
Although epidemiologic studies did not demonstrate an
increased risk of soft tissue sarcomas following hip replace-
ment and silicon breast implant [28, 29], some arguments
support a relationship between chronic repair processes and
soft tissue sarcoma. Several implants were effective inducers of
soft tissue sarcoma in the animal model with malignant fibrous
histiocytoma being the most common subtype [30]. In rodent
models, sarcomas were observed after implantation of various
polymers, silicone, titanium, nickel-chromium, aluminum oxide
[30, 31], silicone elastomer, impermeable cellulose acetate fil-
ters [32], methylchloranthrene [33], and dimethyl hydrazine
[34]. In view of the wide variety of sarcoma-inducing materials,
it has been hypothesized that the tumorigenic effect is mainly
linked to physical properties of the implants rather than with
chemical characteristics [30]. In humans, malignant fibrous
histiocytoma has been found in individual cases after a great
variety of chronic repair processes (table 1) and is the most
commonly observed subtype in this setting [38, 40]. The carci-
nogenic pathways involved are poorly understood. Despite a
conceivable tendency of physicians and patients to seek expla-
nations for tumor growth which might influence the attribution
of tumors to previous trauma or inflammatory lesions in the
literature, it seems likely that the association between chronic
repair processes and the develoment of soft tissue sarcoma is
more than coincidental [38, 40].
Conclusion
Beside the well investigated role of HIV-1 and HHV-8 in the
tumorigenesis of AIDS-related Kaposi’s sarcoma and several
genetically determined disorders, considerable evidence sup-
ports a relationship between occupational chemicals as vinyl
chloride, phenoxyacetic acid herbicides, chlorphenols, dioxin,
medicinal measures as Thorotrast exposure and therapeutic
irradiation, and the development of soft tissue sarcoma.
Hormones and chronic repair processes are further probably
sarcoma-promoting factors. Considering the rarity of soft
tissue sarcomas despite the vast portion that soft tissues com-
prise in the human body, additional knowledge on the tumori-
genesis of soft tissue sarcomas might significantly contribute to
the understanding of the etiologic pathways of malignant tumors
in humans.
Author(s), year [ref.] Location of tumor Involved trauma or inflammatory
lesion
Galli et al., 1977 [35] bone medullary bone infarcts
Weinberg & Maini, 1980 [36] aorta vascular prosthesis
Lee et al., 1984 [37] bone metal implant
Inoshita & Youngberg, 1984 [38] skin amputation; hernioplasty
Yamamura et al., 1984 [39] skin burn scar
Routh et al., 1985 [40] skin chronic ulcer
Lindeman et al., 1990 [41] bone shrapnel trauma
Myoui et al., 1991 [42] pleural cavity tuberculosis
Staiman et al., 1996 [43] testicle/spermatic cord intratesticular injectiona
Cole et al., 1997 [44] bone total hip replacement
Froehner et al., 2000 [45] bladder tuberculosis
a Unethical Nazi medical experimentation at Auschwitz concentration camp.
Table 1. Location and involved trauma or 
inflammatory lesion in malignant fibrous 
histiocytomas found associated with chronic 
repair processes: literature review
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Erratum
Im Abstract-Band ONKOLOGIE 2000;23 (Sonderheft 7) zur Gemeinsamen Jahres-
tagung der ÖGHO/DGHO, Graz, Oktober 2000, sind auf Seite 93 für die Abstracts
Nr. 345 und 346 versehentlich die Autoren nicht korrekt benannt.
Wir bitten zu beachten, dass die Autoren beider Abstracts C. Zang und P.E. Petrides
sind.
